METABOLIC AND CLINICAL EFFECTS OF METHYLANDROSTENEDIOL IN HUMAN SUBJECTS*

Publisher Website
Google Scholar
Abstract
SINCE Kenyon and his associates first demonstrated the growthpromoting effects of testosterone compounds (1), considerable effort has been devoted to the search for a steroid compound which would have the anabolic properties of testosterone, without its androgenic effects. Among the compounds so studied is methylandrostenediol (17α-methyl-A5-androstene-3β-17β-diol). Methylandrostenediol was first synthesized by Ruzicka, Goldberg, and Rosenberg (2) in 1935. Tschopp (3) and Ruzicka and Rosenberg (4) in 1936 demonstrated androgenic activity when large amounts of the compound were administered to experimental animals. In capons, Deanesly and Parkes (5) found its androgenic potency to be one tenth that of testosterone and one half that of methyltestosterone. In mice, Homburger, Forbes and Desjardins (6) reported that methylandrostenediol produced insignificant androgenic effects. In rats, Gordan, Eisenberg and Moon (7) found no androgenic effects in doses of 1 milligram per kilogram but did find effects in doses of 50 milligrams per kilogram, and Deanesly and Parkes (5) felt that methylandrostenediol was one half to two thirds as androgenic as testosterone or methyltestosterone.

This publication has 0 references indexed in Scilit: